Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell cycle arrest at G2/M is a regulatory checkpoint that halts the cell cycle prior to mitosis, allowing cells time to repair DNA damage or incomplete replication before chromosome segregation[1][2][4]. The checkpoint is controlled by a network of kinases and phosphatases (ATM, ATR, Chk1, Chk2, p53, Cdc25, Wee1, etc.), acting primarily on the cyclin B1/CDK1 complex[1][2][3][4]. Dysregulation leads to genomic instability, unchecked cell division, and cancer. Some anticancer agents and DNA damaging drugs exploit this checkpoint to induce apoptosis in rapidly dividing cancer cells. However, the term "cell cycle arrest at G2/M" refers to a process and not to a distinct target molecule or receptor.
Induction of DNA damage to trigger checkpoint activation and halt progress at G2/M[1][3] - Inhibition or activation of checkpoint kinases (ATM, ATR, Chk1, Chk2) - Inhibition of Cdc25 phosphatases (block activation of CDK1/cyclin B1 complex, preventing entry to mitosis) - Disruption of CDK1/cyclin B1 complex and its regulators (Wee1, p21, p53)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on null.